Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Frankel

Showing results (251-260 of 259) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 259 results.
Nature Nanotechnology|April 25, 2017
A STING-activating nanovaccine for cancer immunotherapyMin Luo, Hua Wang, Zhaohui Wang, et al.
Blood|May 27, 2014
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patientsArthur E Frankel, Jung H Woo, Chul Ahn, et al.
Journal of Gastrointestinal Oncology|August 9, 2019
Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinomaMoh'd Khushman, Girijesh Kumar Patel, Javier Ariel Laurini, et al.
Haematologica|November 9, 2014
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agentFanny Angelot-Delettre, Anne Roggy, Arthur E Frankel, et al.
British Journal of Cancer|October 16, 2018
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosisDavid E Gerber, M Shaalan Beg, Farjana Fattah, et al.
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2019
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell CarcinomaKevin D Courtney, Yuanqing Ma, Alberto Diaz de Leon, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Blood|November 18, 2022
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of needNaveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, et al.
Pageof 26

Showing results (251-260 of 259) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 259 results.
Nature Nanotechnology|April 25, 2017
A STING-activating nanovaccine for cancer immunotherapyMin Luo, Hua Wang, Zhaohui Wang, et al.
Blood|May 27, 2014
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patientsArthur E Frankel, Jung H Woo, Chul Ahn, et al.
Journal of Gastrointestinal Oncology|August 9, 2019
Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinomaMoh'd Khushman, Girijesh Kumar Patel, Javier Ariel Laurini, et al.
Haematologica|November 9, 2014
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agentFanny Angelot-Delettre, Anne Roggy, Arthur E Frankel, et al.
British Journal of Cancer|October 16, 2018
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosisDavid E Gerber, M Shaalan Beg, Farjana Fattah, et al.
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2019
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell CarcinomaKevin D Courtney, Yuanqing Ma, Alberto Diaz de Leon, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Blood|November 18, 2022
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of needNaveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, et al.
Pageof 26